Medifast Inc. (NYSE:MED) director Parsa Kiai has disclosed a series of open-market purchases of the company's common stock totaling $1,133,816, according to filings covering transactions on November 18 and 19, 2026. The acquisitions, which spanned two trading sessions, involved 94,036 shares and were executed at prices between $11.855 and $12.20 per share.
The buying activity unfolded as Medifast shares changed hands at $11.75, a level that reflects a decline of more than 9% over the past week. The stock's recent pullback provides the backdrop for the director's purchases, which were made at prices slightly above the prevailing market quote.
Transaction Details
On November 18, 2026, Kiai acquired 8,886 shares at an average price of $12.1613, with individual transaction prices ranging from $12.06 to $12.20. The following day, November 19, 2026, he purchased an additional 85,150 shares at an average price of $12.0464, with prices ranging from $11.855 to $12.15.
All reported shares are held indirectly. The ownership is attributed to Steamboat Capital Partners Master Fund, LP, and Steamboat Capital Partners II, LP. Kiai serves as Managing Member of Steamboat Capital Partners GP, LLC, which acts as the general partner for both funds and has delegated investment discretion to Steamboat Capital Partners, LLC. As a result, Kiai may be deemed to have a pecuniary interest in the shares, though he disclaims beneficial ownership except to that extent.
Following these transactions, Kiai's indirect beneficial ownership of Medifast common stock stands at 828,016 shares.
Recent Financial Results
The insider buying comes after Medifast reported third-quarter 2026 financial results that surpassed Wall Street expectations. The company announced a smaller-than-expected loss, with adjusted earnings showing a negative $0.19 per share, while analysts had projected a loss of $0.62 per share. Revenue for the quarter reached $72.05 million, exceeding the forecasted $67.7 million.
These results indicate a positive trajectory in the company's turnaround efforts, and the earnings report was a key highlight for investors, showing that Medifast is performing better than anticipated.
The stock's recent price action and the director's purchases may draw attention from market participants evaluating the company's valuation and prospects. Medifast shares closed at $11.75 on the day of the disclosure, down $0.23 or 1.92%.